Pfizer, BioNTech stocks rally after announcing positive trial data on BA.4/BA.5 bivalent booster shot


Pfizer Inc. PFE, +1.40% and Germany-based partner BioNTech SE BNTX, +6.24% said new data from a Phase 2/3 trial showed that the booster for companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine demonstrated a “robust neutralizing immune response” after one month. The companies said immune responses for those getting the booster were “substantially higher” than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles. “As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating omicron BA.4 and BA.5 sublineages,” said Pfizer Chief Executive Albert Bourla. The news comes after The Wall Street Journal reported that China agreed to approve the companies’ COVID-19 vaccine for foreign residents in China. Shares of Pfizer rallied 1.8% and BioNTech climbed 6.2% premarket, while futures ES00, -0.18% for the S&P 500 SPX, +1.36% rose 0.9%.

This article was originally published by Read the original article here.

Previous article: Twitter launches new $8 subscriptions for verification, days before U.S. midterm elections
Next articleHelp My Career: What can I do to improve my salary? Am I being paid fairly? In a strong jobs market, here’s how to push for a pay raise.


Please enter your comment!
Please enter your name here